All In Biotech

Drug Trial Radar · NCT07778446

A Study to Test CRT-402 in Refractory Autoimmune Disease

A Phase 1/2 Dose Escalation and Expansion Study of CRT-402, an In Vivo CD19 Targeted CAR-T Therapy, in Refractory Autoimmune Disease

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

34

Planned (sponsor's estimate)

Start

Aug 26, 2026

Primary completion

Dec 1, 2028

Study completion Aug 1, 2029

Sponsor

Lead sponsor
Myeloid TherapeuticsIndustry
Sponsor type
Industry
Collaborators
CREATE Medicines
First posted
Aug 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients with refractory autoimmune diseases often have limited treatment options and ongoing disease activity despite standard therapies. CRT-402 is an in vivo Cluster of differentiation 19 (CD19)-targeted CAR-T cell therapy designed to deplete CD19-positive B cells and promote immune system reset. This study evaluates the safety, tolerability, preliminary efficacy, pharmacodynamics (PD), and pharmacokinetics (PK) of CRT-402 in participants with active refractory systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and idiopathic inflammatory myopathies (IIM).

Conditions

  • Autoimmune Diseases
  • Systemic Lupus Erythematosus
  • Systemic Scleroderma
  • Myositis

Interventions

  • CRT-402Drug

    CRT-402 administered by intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs), and dose-limiting toxicities (DLTs).Time frame: Up to 52 weeks
  2. Incidence and severity of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).Time frame: Up to 52 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Linear Advanced Clinical Trial Centre, Ground Floor, B Block, Queen Elizabeth II Medical Centre, Hospital Avenue

    Nedlands, Western Australia, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.